The interactions between chemokines and their receptors may have an important role in initiating GVHD after allogeneic hematopoietic SCT (allo-HSCT). CCL25 and CCR9 are unique because they are exclusively expressed in epithelial cells and in Peyer's patches of the small intestine. We focused on rs12721497 (G926A), one of the non-synonymous single nucleotide polymorphisms (SNPs) in the CCR9 gene, and analyzed the SNP of donors in 167 consecutive patients who received allo-HSCT from an HLA-identical sibling donor. Genotypes were tested for associations with acute and chronic GVHD in each organ and transplant outcome. Multivariate analyses showed that the genotype 926AG was significantly associated with the incidence of acute stage X2 skin GVHD (hazard ratio: 3.2; 95% confidence interval (95% CI): 1.1-9.1; P ¼ 0.032) and chronic skin GVHD (hazard ratio: 4.1; 95% CI: 1.1-15; P ¼ 0.036), but not with GVHD in other organs or with relapse, non-relapse mortality or OS. To clarify the functional differences between genotypes, each SNP in retroviral vectors was transfected into Jurkat cells. In chemotaxis assays, the 926G transfectant showed greater response to CCL25 than the 926A transfectant. In conclusion, more active homing of CCR9-926AG T cells to Peyer's patches may produce changes in Ag presentation and result in increased incidence of skin GVHD.
Introduction
Acute GVHD is a severe complication of allogeneic hematopoietic SCT (allo-HSCT). 1 After Ag presentation in secondary lymphoid tissues, migration of activated donor T lymphocytes to target organs has a central role in its induction. Recent studies have shown that the migration of lymphocytes to secondary lymphoid tissues or target organs, such as the skin, liver and gut, is regulated by specific chemokines. 2, 3 Chemokines are a group of small molecules that regulate the trafficking of leukocytes through interactions with a subset of seven transmembrane, G protein-coupled receptors (chemokine receptors). 4, 5 Their interactions may have an important role in initiating organ-specific GVHD.
Sites of expression are ubiquitous in many chemokines. For example, CCL17, which is well known as a skinhoming chemokine, is also expressed in many other organs, including the adrenal gland, bronchus, cerebellum, colon, heart and liver. 4 CCL28 is expressed by epithelial cells in several mucosal tissues, including the trachea, small intestine, colon, rectum, salivary gland and mammary gland. 6, 7 By contrast, CCL25 (thymus-expressed chemokine) and its receptor CCR9 are unique because, outside the thymus, they are almost exclusively expressed by epithelial cells and Peyer's patches in the small intestine. [8] [9] [10] Therefore, we focused on CCR9 because it may influence the onset of intestinal GVHD or Ag presentation in Peyer's patches.
The CCR9 gene is located on chromosome 3p21.3. A variety of single nucleotide polymorphisms (SNPs) in the CCR9 gene have been reported, although their functional differences are not yet known. Within these SNPs, rs12721497 (G926A) is non-synonymous in exons, and it is the sole SNP whose frequency and linkage disequilibrium have been reported. This SNP alters the CCR9 amino acid sequence of the third exoloop from Val272 to Met272. We hypothesize that this SNP may have an effect on the onset of GVHD and transplant outcome because of the differences in the tissue-specific migration of T lymphocytes.
Materials and methods

Patients
A total of 186 consecutive patients received allogeneic BM or PBSC transplantation from an HLA-identical sibling donor at the Nagoya University Hospital and the Japanese Red Cross Nagoya First Hospital between 1987 and 2006. HLA matching among donor-recipient pairs was confirmed by either family study or genotyping in all patients. Of these 186 patients, 167 who received T-cell-replete transplantation and CYA in combination with short-term MTX as a GVHD prophylaxis were selected to participate in the study. CYA was administered daily at 3.0 mg/kg from day 1 as an i.v. infusion, and then switched to an oral dose at twice the i.v. dose when oral intake resumed. MTX was administered at 10 mg/m 2 on day 1 and, on days 3 and 6, was administered at 7 mg/m 2 . Informed consent was obtained from all patients and donors, and the study was approved by the ethics committees at the Nagoya University Hospital and Japanese Red Cross Nagoya First Hospital.
Allellic discrimination of the polymorphism G926A in the CCR9 gene The CCR9-G926A polymorphism (rs12721497) was determined by the PCR-RFLP method using genomic DNA obtained from donor PBMCs. The primers used for PCR were 5 0 -CACACCCTGATACAAGCCAA (forward) and 5 0 -CTCCAGCAACATAGACGACA (reverse). Sequences of interest were amplified by PCR, using Advantage II Polymerase Mix (Clontech Laboratories, Mountain View, CA, USA) in reaction mixtures containing 0.5 ml of genomic DNA and 10 pmol of each primer in a volume of 20 ml. Amplifications were performed using 35 cycles of denaturation at 95 1C for 30 s, annealing at 65 1C for 15 s and elongation at 72 1C for 30 s on a model 9600 thermocycler (Perkin-Elmer, Norwalk, CT, USA). After amplification, the 369-bp CCR9 fragment was digested for 2 h at 37 1C with 5 U of NLAIII (New England BioLabs, Ipswich, MA, USA) in a 20 ml reaction mixture. The digested products were analyzed by electrophoresis on a 1.5% agarose gel. Wild-type (AA) individuals were identified by the presence of only a 369-bp fragment, heterozygotes (AG) by the presence of both 231/138-and 369-bp fragments and homozygotes (GG) by the presence of only the 231-and 138-bp fragments. To rule out the incomplete digestion of the AG genotype, PCR products of this genotype were directly sequenced using the Applied Biosystems 310 automated DNA sequencer (Applied Biosystems, Foster City, CA, USA) following the manufacturer's instructions.
Site-directed mutagenesis and construction of CCR9-926A and 926G expression vectors Site-directed mutagenesis of the human wild-type CCR9 cDNA in pF1K vector (purchased from Kazusa DNA Research Institute, Kisarazu, Chiba, Japan) was carried out using the Quickchange Kit (Stratagene, La Jolla, CA, USA). Synthetic oligonucleotide primers containing the corresponding 926G point mutation had the following sequences: 5 0 -CCATTGACGCCTATGCCGTGTTCATC TCCAACTGT (forward) and 5 0 -ACAGTTGGAGA TGAACACGGCATAGGCGTCAATGG (reverse). The oligonucleotide was amplified with Pfu turbo DNA polymerase (Stratagene), and the template plasmid was digested by DpnI. Each sequence of CCR9 cDNA was amplified by PCR with primers containing the following EcoRI/NotI sites: 5 0 -CGCGGAATTCATGACACCCAC AGACTTCACA (forward) and 5 0 -ATCGGCGGCCGC TCAGAGGGAGAGTGCTCCTGAGGT (reverse). Each product was cut at EcoRI/NotI sites, and ligated into pMX-IRES-Puro (a kind gift from Dr Toshio Kitamura, University of Tokyo), which had been digested with EcoRI and NotI. The final construct used for cell transfection was sequenced entirely to verify the presence of the mutation and to ensure that no other variant was accidentally introduced during DNA amplification.
Retrovirus transfection
PLAT-A packaging cells (a kind gift from Dr Toshio Kitamura, University of Tokyo) were used to produce recombinant retrovirus particles.
11 PLAT-A cells were transfected with retroviral vectors using FuGENE6 (Roche, Indianapolis, MN, USA). Jurkat cells were infected with each of the pMX-CCR9-926A-IRES-Puro, pMX-CCR9-926G-IRES-Puro and pMX-IRES-Puro (control) retroviruses. The cells were washed once and resuspended in the fresh selection medium containing 500 ng/ml of puromycin (Cayla, Toulouse, France), 48 h after transfection .
Flow cytometric analysis
Phycoerythrin-labeled monoclonal anti-CCR9 (112509) was purchased from R&D Systems (Minneapolis, MN, USA). Analyses were carried out on FACSAria (BD Biosciences, San Jose, CA, USA) using the FlowJo software (Treestar, San Carlos, CA, USA).
Chemotaxis assays
Chemotaxis assays were carried out as previously described 12 using 6.5-mm-thick Transwell tissue culture inserts with a 5-mm pore size (Corning, Corning, NY, USA). The transfected cell lines were starved overnight in the plain RPMI 1640 medium, suspended at 1 Â 10 7 cells per ml in this medium with 0.1% of BSA, and 100 ml of cell suspension was added to an upper insert in a lower well with 600 ml of the medium. After equilibration at 37 1C for 2 h, various concentrations (0-2000 ng/ml) of recombinant human CCL25 (R&D Systems) were added to the lower wells, and the plates were incubated for an additional 90 min before migrated cells in the lower well were counted.
Statistical analysis
OS was calculated from the date of transplantation to the date of death from any cause using the Kaplan-Meier method, and P-values were calculated using a log-rank test. Non-relapse mortality (NRM) was defined as mortality due to any cause other than relapse or disease progression. Cumulative incidences of NRM and relapse were estimated CCR9 gene polymorphism and GVHD Y Inamoto et al using Gray's method, with relapse and NRM, respectively, as a competing risk. Acute GVHD was graded by established criteria. 13 Chronic GVHD was evaluated in patients who survived beyond day þ 100, and was classified as limited or extensive according to the Seattle criteria.
14 A multivariate Cox model was created for grade II-IV acute GVHD, organ stages of acute GVHD, chronic GVHD, OS, NRM and relapse using stepwise selection at a significance level of 5%. Age, conditioning, disease risk, remission state, donor-recipient sex combination and graft source were used as covariates. For chronic GVHD analysis, a history of acute GVHD was included as covariates. Hazard ratios of the CCR9 genotype were adjusted by these models. In acute GVHD analysis, patients who died before day þ 30 were censored. Analysis was carried out using STATA (StataCorp. 2007; Stata Statistical Software: Release 10.0. Special Edition. Stata Corporation, College Station, TX, USA). Data analyses were completed as of January 2007 using the most updated database at each institute.
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . Ninetyfour male patients and 73 female patients, with a median age of 38 years, were included in the study. Our patients were afflicted with various diseases, including myeloid malignancies (n ¼ 106), lymphoid malignancies (n ¼ 42) and benign diseases (n ¼ 19). Disease risk was standard in 97 patients and high in 70 patients. Standard risk included malignancies in the first and second remission, chronic myelogenous leukemia in the chronic phase, myelodysplastic syndrome with refractory anemia with or without ringed sideroblasts and benign diseases. High risk included all others. Ninety-eight patients with malignant disease received transplantation with their disease in remission. The graft source was BM in 130 patients and PBSCs in 37 patients. The conditioning regimen was myeloablative in 147 patients and reduced-intensity conditioning in 20 patients. TBI was used as part of the conditioning in 98 patients. Myeloablative conditioning regimens for malignancy included BU 16 mg/kg þ CY 120 mg/kg (n ¼ 32), CY 120 mg/kg þ TBI 12 Gy (n ¼ 9), CY 120 mg/kg þ TBI 10 Gy þ another agent of BU 8 mg/kg, cytarabine 8 g/m 2 , etoposide 50 mg/kg or melphalan 140 mg/m 2 (n ¼ 62), BU 8 mg/kg þ melphalan 180 mg/m 2 þ TBI 10 Gy (n ¼ 12) and melphalan 180 mg/m 2 þ TBI 10 Gy (n ¼ 13). Reducedintensity conditioning regimens for malignancy included fludarabine 125 mg/m 2 þ melphalan 100-180 mg/m 2 (n ¼ 20). Conditioning regimens for aplastic anemia included CY 200 mg/kg þ TLI 7.5 Gy (n ¼ 17) and CY 200 mg/kg þ TLI 5 Gy þ TBI 5 Gy (n ¼ 1) as previously described. 15 One patient with paroxysmal nocturnal hemoglobinuria was conditioned with CY 120 mg/kg þ TBI 12 Gy. At a median follow-up of 42 months (range: 2-220 months), 104 patients were still alive. The estimated 4-year OS, NRM and relapse rates were 55, 18 and 30%, respectively. Causes of 26 non-relapse mortalities included bronchiolitis obliterans (n ¼ 2), idiopathic pneumonia syndrome (n ¼ 8), hepatic failure (n ¼ 1), veno-occlusive 
, scleroderma (n ¼ 1) and bacterial or fungal pneumonia (n ¼ 3). The incidence rates of grade II-IV, III-IV acute GVHD and chronic limited/extensive GVHD were 18.6, 6.6 and 41%, respectively. The incidence rates of stage 2-4 skin, liver and gut involvement were 18, 3 and 6%, respectively.
Frequency of CCR9 genotypes
Ten donors had genotype 926AG by the RFLP method, which was subsequently confirmed using direct sequence. The frequencies of the 926AA, 926AG and 926GG genotypes among the donors were 94, 6 and 0%, respectively, which were comparable with those reported in the HapMap-JPT database (http://www.hapmap.org).
Hazard analysis and the effect of CCR9 genotypes on transplant outcome
The proportion of patients who developed GVHD in each genotype is summarized in Table 2 . Grade II-IV GVHD, stage 2-4 skin GVHD, stage 2-4 liver GVHD, stage 2-4 gut GVHD and chronic limited/extensive GVHD developed in 2, 4, 1, 1 and 4 patients, respectively, among patients whose donor had the genotype 926AG, whereas they developed in 29, 26, 4, 9 and 60 patients, respectively, among patients whose donor had the genotype 926AA. The estimated 4-year OS, NRM and relapse rates were not significantly different between G926A genotypes (56 vs 55%, P ¼ 0.78; 33 vs 17%, P ¼ 0.32; 10 vs 32%, P ¼ 0.19, respectively) ( Figure 1 ). Multivariate analyses showed that PBSC transplantation was a risk factor for grade II-IV GVHD, stage 2-4 skin GVHD and stage 2-4 gut GVHD; high risk disease was a risk factor for OS and relapse; age of more than 40 years was a risk factor for OS and NRM; and female-to-male transplantation was a risk factor for chronic liver GVHD (Table 3 , middle column). Hazard ratios of the genotype 926AG, adjusted by these factors, are listed in Table 3 (right column). The genotype 926AG was significantly associated with acute stage 2-4 skin GVHD (hazard ratio: 3.2; 95% confidence interval (95% CI): 1.1-9.1; P ¼ 0.032) and chronic skin GVHD (hazard ratio: 4.1; 95% CI: 1.1-15; P ¼ 0.036), whereas it was not associated with grade II-IV GVHD or with stage 2-4 liver GVHD, stage 2-4 gut GVHD, limited or extensive chronic GVHD, chronic GVHD in organs other than skin, OS, NRM or relapse. PBSCs were used in only 1 of 10 patients who received transplantation from 926AG donors.
Functional comparison between CCR9-926A and 926G
To clarify the functional differences between genotypes of 926A and 926G, we created cDNA constructs with each genotype using the Quickchange Kit. Each construct was transfected into Jurkat cells with retroviral vectors. After 3 weeks of selection with puromycin, we analyzed the expression of CCR9 in each of the stably transfected cells. Cells were stained with phycoerythrin-labeled monoclonal anti-CCR9. The level of CCR9 expression was higher in CCR9-transfected cells compared with that in controltransfected cells, and equivalent between the 926A and 926G genotypes (Figure 2a) . We next analyzed the migration of Jurkat cells transfected with control vectors, 926A and 926G, as well as plain Jurkat cells in response to varying concentrations of CCL25, using porous Transwell tissue culture inserts to separate the cells in the upper chambers from the chemokine-containing medium in the lower chambers. As shown in Figure 2b , CCR9-transfected cells, but not the control-transfected or plain Jurkat cells, migrated in response to CCL25 in a dose-dependent manner, producing a bell-shaped curve. It is noted that CCR9-926G-expressing cells were more responsive to CCL25 compared with those expressing CCR9-926A.
Discussion
Several genetic polymorphisms of inflammatory cytokine genes are reported to affect the outcome of allo-HSCT. [16] [17] [18] [19] [20] [21] Chemokines are another group of cytokines that control the trafficking of leukocytes through interactions with chemokine receptors. We hope to clarify the role of these Figure 1 Overall survival between G926A genotypes. At a median follow-up of 42 months (range: 2-220 months), the estimated 4-year overall survival was not statistically different between G926A genotypes (56 vs 55%, P ¼ 0.78).
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Y Inamoto et al chemokines in initiating GVHD. Specifically, we address the association of polymorphism in the tissue-specific chemokine receptor gene with acute and chronic GVHD and the regulation of leukocyte trafficking. CCL25 and CCR9 (as chemokine and chemokine receptor) are selectively expressed in both the thymus and the small intestine. 22, 23 One of their important functions is the selective homing and retention of CCR9-positive T cells and B cells to the small intestine rather than to the colon, which provides a mechanism for regional specialization of the mucosal immune system. 9, 24 Another function is regulating intrathymic T-cell development, particularly double-negative to double-positive transition, 25, 26 which may be associated with T-cell recovery after allo-HSCT. Therefore, the effect of the CCR9 genotype on acute GVHD is hypothesized to result from its function in the small intestine because T cells educated in the thymus will appear at least 6 months after transplantation. 27 Interestingly, donor CCR9 SNPs affected the incidence of skin GVHD, but did not affect the incidence of intestinal GVHD. This observation may be partially explained by the findings of Beilhack et al., 28 who recently reported the redundancy of secondary lymphoid organs at different anatomical sites in GVHD initiation. They suggested that primed T cells could initiate GVHD at sites other than their original priming sites. As Peyer's patches are important sites of Ag presentation, 29 differences in T cell homing to Peyer's patches between each CCR9 genotype may produce changes in Ag presentation and result in varying incidences of skin GVHD.
Our results suggest the possibility of CCL25/CCR9-targeting modalities for GVHD. CCL25 and CCR9 have an important role in the adherence of T lymphocytes to the intestinal endothelium under inflammatory and normal conditions, and anti-CCL25 Ab attenuates the TNF-ainduced T-cell adhesion in the small intestine. 30 Although blocking the interactions of CCL25 and CCR9 may delay immunological reconstitution in the thymus, CCR9-deficient mice showed no major effect on intrathymic T-cell development despite a 1-day lag in the appearance of double-positive cells and a diminution of gd-T cells. 31 One possible limitation of this study is that genetic associations can be biased by population stratification, 32 and there is also the chance of false-positive associations with the CCR9 genotype on the basis of multiple statistical tests. Confirmation of the results with another separate cohort is needed for eliminating a possible confounding effect. Another limitation is that this SNP might be in linkage disequilibrium with SNPs in the CCR9 gene or in the other genes located nearby. Linkage disequilibrium mapping of CCR9 using the HapMap-JPT database showed one small block in introns of the CCR9 gene, but G926A was outside the block with no known associations with other SNPs in the CCR9 gene or with genes located around chromosome 3p21.3. In addition, this SNP alters CCR9 amino acid sequences of the third exoloop, which is an important site for chemokine binding and specificity. 33 Therefore, this SNP can affect biological functions due to altered efficiencies of the receptor or signal transduction from the receptor. Although Transwell assays using SNP-transfected cells showed that biological functions varied according to this SNP, the elucidation of additional mechanisms are matters for future research.
In summary, this study suggests that donor 926AG is associated with an increased incidence of acute and chronic skin GVHD in related HSCT recipients. CCL25 and CCR9 
